Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Clinical trial NCT05308901 · TERMINATED
Trial details
- NCT number
- NCT05308901
- Sponsor
- Providence Health & Services
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-02
- Primary completion
- 2024-12-03
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.